Home / Specialty Pharmacy (page 10)

Specialty Pharmacy

Enanta’s Announces Positive Early-Stage Results for its Lead FXR Agonist

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced positive results from its Phase 1 clinical study of EDP-305, Enanta’s lead FXR agonist for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). The objective of …

Read More »

Express Scripts Acquires eviCore for $3.6 Billion, Accelerating its Shift to Patient Benefit Management

LOUIS and BLUFFTON, S.C., Oct. 10, 2017 /PRNewswire/ — Express Scripts Holding Company (NASDAQ: ESRX) today announced that it has reached an agreement to acquire privately-held eviCore healthcare, the industry leader in evidence-based medical benefit management services, for $3.6 billion. Combining Express Scripts’ leading pharmacy benefit management offering and eviCore’s …

Read More »

FDA Grants Orphan Drug Designation to Kadmon’s Chronic Graft-Versus-Host Disease Treatment

NEW YORK–(BUSINESS WIRE)–Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KD025, the Company’s Rho-associated coiled-coil kinase (ROCK) inhibitor, for the treatment of chronic graft-versus-host disease (cGVHD), a serious complication following allogeneic bone marrow or stem cell transplantation. KD025 …

Read More »

Biogen’s Spinraza Data Show Initiating Treatment Earlier May Improve Motor Function in SMA

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) presented new data demonstrating that earlier initiation of treatment with SPINRAZA® (nusinersen) may improve motor function outcomes in infants and children with spinal muscular atrophy (SMA). Results continued to reinforce the favorable efficacy and safety profile of SPINRAZA. The data were shared at the 22nd International Annual Congress …

Read More »

Celgene and Nimbus Enter Immunology Alliance to Develop Programs for Autoimmune Disorders

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, announced today the initiation of a long-term strategic alliance with Celgene Corporation (NASDAQ: CELG) in immunology. Under the terms of the agreement, Celgene will receive an option to acquire each program in the alliance …

Read More »

Zynerba’s Cannabis-Based Drug Demonstrates Positive Results in Study in Fragile X Syndrome

DEVON, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced positive top line results from an open label exploratory Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol …

Read More »

FDA Commissioner Gottlieb on New Efforts to Encourage Compounding of Better Quality Drugs Under DQSA

As a physician, I understand how important it is for health care providers to have access to compounded drugs when the needs of their patients cannot be met by FDA-approved drugs. Our commitment to implementing and enforcing the Drug Quality and Security Act (DQSA) provides a pivotal foundation for achieving …

Read More »

Anthem, Inc. to Acquire HealthSun

INDIANAPOLIS–(BUSINESS WIRE)–Anthem, Inc. (NYSE:ANTM) today announced that the company has entered into an agreement to acquire HealthSun, one of the fastest-growing integrated Medicare Advantage health plans and healthcare delivery networks in Florida. “Anthem is committed to identifying opportunities for growth that will enable us to advance our goal of increasing …

Read More »

Genentech’s Actemra Receives FDA Approval for the Treatment of CAR-T Cell-Induced Cytokine Release Syndrome

South San Francisco, CA — August 30, 2017 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra®(tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release …

Read More »

FDA Approves Teva’s Austedo for Treatment of Tardive Dyskinesia in Adults

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. AUSTEDO® was previously approved for the treatment of chorea associated with Huntington’s disease in April 2017. Tardive dyskinesia is a …

Read More »